Evidence map›Paper›PMID 27541595›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Sentinel lymph node biopsy as a prognostic factor in non-metastatic colon cancer: a prospective study.

O Estrada, L Pulido, C Admella, L-A Hidalgo, P Clavé, X Suñol

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Cancer spreading patterns based on epithelial-mesenchymal plasticity.Frontiers in cell and developmental biology · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

O EstradaGeneral Surgery Department, Colorectal Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain. oestrada@csdm.cat.
L PulidoGeneral Surgery Department, Colorectal Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.
C AdmellaPathology Department, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.
L-A HidalgoGeneral Surgery Department, Colorectal Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.
P ClavéGeneral Surgery Department, Colorectal Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.
X SuñolGeneral Surgery Department, Colorectal Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain.
Hospital de Mataró · ESMaresme Health Consortium · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAround a third of node-negative patients with colon cancer experience a recurrence after surgery, suggesting poor staging. Sentinel lymph node techniques combined with immunochemistry could improve colon cancer staging. We prospectively assessed the effect of Sentinel node mapping on staging and survival in patients with non-metastatic colon cancer.

methodsAn observational and prospective study was designed. 105 patients with colon cancer were selected. Patients were classified according to node involvement as: N1, with node invasion detected by the conventional techniques; up-staged, with node invasion detected only by sentinel node mapping; and N0, with negative lymph node involvement by both techniques. Five-year survival and disease-free survival rates were analysed. Multivariate regression analyses were performed to identify prognostic factors for disease-free and overall survival.

resultsSentinel node mapping was successfully applied in 78 patients: 33 % were N1; 24.5 % were up-staged (18 patients with isolated tumour cells and 1 patient with micrometastases); and 42.5 % were N0. N1 patients had the poorest overall 5-year survival (65.4 %) and 5-year disease-free survival (69.2 %) rates compared with the other two groups. No significant 5-year survival differences were observed between N0 patients (87.9 %) and up-staged patients (84.2 %).

conclusionsPatients up-staged after sentinel node mapping do not have a poorer prognosis than patients without node involvement. Detection of isolated cancer cells was not a poor prognosis factor in these patients.

Indexed as

Sentinel Lymph Node BiopsyAgedColectomyColonic NeoplasmsFemaleFollow-Up StudiesHumansMaleNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProspective StudiesSurvival RateColorectal cancerIsolated cancer cellsSentinel nodeUp-stage

Identifiers

PMID27541595
OpenAlexW2508331953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.